

1 **SUPPLEMENTAL MATERIAL**

2

3 **SUPPLEMENTAL METHODS**

4 **Transient middle cerebral artery occlusion (tMCAO)**

5 Surgery. Anesthesia was induced in mice by 3% isoflurane in a N<sub>2</sub>O/O<sub>2</sub> (70/30%)  
6 mixture and maintained by 1-1.5% isoflurane in N<sub>2</sub>O/O<sub>2</sub> (70/30%) mixture. Transient  
7 ischemia was achieved by middle cerebral artery (MCA) occlusion[1, 2] by means of  
8 a siliconized filament (7-0, Doccol Corp.) introduced into the internal right carotid  
9 artery, pushed onwards till the origin of the MCA for 60 min. At the end of the  
10 ischemic period the filament was withdrawn and reperfusion was allowed. All mice  
11 were maintained at 37°C during surgery using a heating pad (LSI Letica). Surgery-  
12 associated mortality rate was 7%.

13 Neurological deficits. All mice following tMCAO were assessed on an open bench  
14 top. In a neurological scoring system where 0 represents healthy and 56 the worst  
15 neurological outcome, the general and focal deficits were assessed. The general  
16 deficits describing general well being of the mice, were attributed with a maximum  
17 scoring of 28, assessing hair (0-2), ears (0-2), eyes (0-4), posture (0-4), spontaneous  
18 activity (0-4) and epileptic behaviour (0-12). Mice were assessed for focal deficits  
19 according to body symmetry (0-4), gait (0-4), climbing on a 45° surface (0-4), circling  
20 behaviour (0-4), forelimb symmetry (0-4), compulsory circling (0-4) and whisker  
21 response (0-4) with a maximum scoring of 28 [3].

22 Infarct volume quantification. Perfused brains were obtained as described  
23 previously[1]. Twenty-micron coronal brain cryosections were cut serially at 320 µm

24 intervals and stained with cresyl violet (Sigma-Aldrich). Ischemic lesion was  
25 calculated on seven slices from bregma +2 mm to -3.76 mm by delineating by the  
26 relative paleness of histological staining tracing the area on a video screen. Infarct  
27 volumes were calculated by the integration of infarcted areas after correction for the  
28 percentage of brain swelling due to edema. Edema was determined by subtracting the  
29 area of the ipsilateral from that of the contralateral hemisphere. Quantifications were  
30 performed using a computer-assisted image analyzer and calculated by Analytical  
31 Image System (Imaging Research Inc.)[3].

### 32 **3 Vessel Occlusion (3VO)**

33 Surgery. Buprenorphine (Vetergesic) diluted in saline (0.1mg/kg) was pre-operatively  
34 administered to the animals as an analgesic. Initial anaesthesia was induced with a  
35 mixture of 3 L/min isoflurane followed by maintenance anaesthesia at 1 to 2 L/min.  
36 O<sub>2</sub> and N<sub>2</sub>O levels were kept constant at 1L/min and 0.8L/min respectively. Body  
37 temperature was maintained at 36°C. As described by Yanamoto *et al.* 2003 [4], via a  
38 ventral midline incision of the neck, the two common carotid arteries (CCA) were  
39 exposed followed by clamping of the left CCA using an aneurism clip. Following the  
40 left CCA clipping, the left zygomatic arch was removed to enable access to the skull  
41 and the middle cerebral artery. A 1 mm thick burr hole was opened 1 mm superior–  
42 rostral to the foramen ovale to allow access to the MCA followed by its permanent  
43 cauterisation using a bipolar coagulator (Aura, Kirwan Surgical Products).  
44 Cauterisation was performed at the lateral edge of the left olfactory tract. Following  
45 the MCA occlusion, complete ischemia was induced for 30 minutes by the clipping of  
46 the right CCA. At 30 min of ischemia, both clips were removed allowing reperfusion  
47 for 24 h. Surgery-associated mortality rate was 8%.

48 TTC staining. After 24h of reperfusion mice were killed via cervical dislocation and  
49 brains were removed and sliced into 1 mm thick slices using a pre-cooled brain  
50 matrix. Infarct size volume after ischemia was measured using 2, 3, 5-  
51 triphenyltetrazolium chloride (TTC). The red colouring in brain sections indicates the  
52 normal, non-infarcted tissue whereas non-coloured, white areas indicate the infarcted  
53 tissue. Brain sections were stained with 2% TTC in saline at room temperature for 30  
54 min in the dark. Afterwards the sections were fixed in 10% formalin (Sigma) and  
55 stored in the dark at 4°C. Digital images were taken and analysed using Image J  
56 software designed to calculate the infarct volume.

#### 57 **Pharmacodynamic activity assay**

58 To assess the pharmacodynamic effect of MASP-2 mAb administration in mice,  
59 systemic lectin pathway activity was evaluated by quantifying lectin-induced C3  
60 activation in minimally diluted serum samples collected at the indicated time after  
61 MASP-2 mAb or control mAb administration to mice. Briefly, 7µm diameter  
62 polystyrene microspheres (Bang Laboratories) were coated with Mannan by overnight  
63 incubation with 33µg/mL of Mannan (Sigma) in of sodium carbonate-bicarbonate  
64 buffer (pH 9.6), then washed, blocked with 1% BSA in PBS and resuspended in PBS  
65 at a final concentration of  $1 \times 10^8$  beads/mL. Complement deposition reactions were  
66 initiated by the addition of 2.5 µL of mannan-coated beads (~250,000 beads) to 50µL  
67 of minimally diluted mouse serum sample (90% final serum concentration), followed  
68 by incubation for 40 min at 4°C. Following termination of the deposition reaction by  
69 the addition of 250 µL of ice-cold flow cytometry buffer (FB: PBS containing 1%  
70 BSA), beads were collected by centrifugation (3000 x g for 3 min at 4°C) and washed  
71 two more times with 300 µL of ice-cold FB.

72 To quantify lectin-induced C3 activation, beads were incubated for 1 hour at 4°C with  
73 50 µL of rabbit anti-human C3c antibody (Dako) diluted in FB. Following two washes  
74 with FB to remove unbound material, the beads were incubated for 30 min at 4°C with  
75 50 µL of goat anti-rabbit antibody conjugated to PE-Cy5 (Southern Biotech) diluted  
76 in FB. Following two washes with FB to remove unbound material, the beads were  
77 resuspended in FB and analyzed by a FACS Calibur cytometer. The beads were gated  
78 as a uniform population using forward and side scatter, and C3b deposition in each  
79 samples was quantified as mean fluorescent intensity (MFI).


#### 80 **Immunofluorescence and confocal analysis**

81 Immunofluorescence was performed on 20-µm coronal sections as previously  
82 described[3]. Brain sections were incubated with rat anti-mouse CD11b (1:500, kindly  
83 provided by Dr.Doni) and rabbit anti-C3 polyclonal (Santa Cruz Biotechnology)  
84 primary antibodies. Alexa 546 anti-rat and Alexa 488 anti-rabbit (both 1:500,  
85 Invitrogen) were used as secondary antibodies. Appropriate negative controls without  
86 the primary antibodies were performed and none of immunofluorescence reactions  
87 revealed unspecific fluorescent signal. Immunofluorescence was acquired using a  
88 scanning sequential mode to avoid bleed-through effects by an IX81 microscope  
89 equipped with a confocal scan unitbFV500 with three laser lines: Ar-Kr (488 nm),  
90 He-Ne red (646 nm), and He-Ne green (532 nm, Olympus, Tokyo, Japan) and a UV  
91 diode. Three-dimensional images were acquired over a 10-µm z-axis with a 0.23-µm  
92 step size and processed using Imaris software (Bitplane, Zurich, Switzerland) and  
93 Photoshop CS2 (Adobe Systems Europe Ltd).

#### 94 **CD11b immunohistochemical analysis**

95 Slice selection and quantitative analysis. Field selection was performed on one brain  
96 coronal section (+0.1 mm from bregma, **Fig 1S**) using a BX61 Olympus microscope  
97 equipped with a motorized stage, acquiring the focal plane corresponding to image  
98 maximal sharpness (best focus) as calculated by the acquisition software AnalySIS  
99 (Olympus)[5, 6]. Twelve quantification fields at  $\times 40$  magnification (pixel size =  $0.172$   
100  $\mu\text{m}$ ) were uniformly distributed over the cortex. Centres of frames at  $\times 40$  were  
101 distanced  $532 \mu\text{m}$  for horizontally aligned frames and  $266 \mu\text{m}$  for vertically aligned  
102 frames. The gap between subsequent frames was chosen to avoid overlapping  
103 acquisitions (frame centres were distanced  $89.5$  and  $66.5 \mu\text{m}$  from frame boundaries),  
104 thus preventing cells from appearing twice in consecutive frames.

105



**Figure 1S. Distribution of acquisition fields.** In WT (A), MASP-2 KO (B) and MASP-1/3 KO mice, twelve  $40\times$  magnification fields were acquired over a cortical area involved in the ischemic lesion as evidenced by the red line. Acquisition fields were placed using a motorized stage microscope to enable unbiased sampling.


112

113 Image processing was performed using Fiji software[7] through the algorithm  
114 previously described[6]. Briefly, to ensure selecting only cells entirely present in the  
115 acquired field, cells with an area  $>25 \mu\text{m}^2$  were analyzed and cells on the boundaries  
116 were excluded. Once segmented, the objects meeting the minimum size to be  
117 analyzed were measured for the following parameters: area, Feret's diameter (caliper)  
118 and solidity. Mean single cell values for each parameter were used for statistics.

119 **Cerebral vessel staining**

120 Cerebral vessels were stained as described by Hasan[8] with slight modifications.  
121 Mice were transcardially perfused with warm PBS followed by a mixture of two  
122 commercially available inks, Pelikan Stempelfarbe ink and Pelikan calligraphy ink  
123 (1:9, respectively). Brains were then removed and fixed overnight with 4%  
124 paraformaldehyde. The image of the right hemisphere was taken from WT and  
125 transgenic mice. The anastomotic line between the MCA and anterior carotid artery  
126 (ACA) was drawn and the distance between the brain midline and the anastomotic  
127 line was measured at 4mm and 6mm distance from the frontal pole.

128




130

131

132 **Figure 2S**

133 **Pharmacodynamics of MASP-2 mAb HG4 in mice.** Groups of mice were injected  
 134 intraperitoneally with 5mg/kg of mAb HG4 (open circles) or isotype control  
 135 (squares). At 1 day, 3 days or 7 days after injection, mice were euthanized, bled and  
 136 LP functional activity evaluated in highly concentrated serum (90%) measuring C3b  
 137 deposition on mannan coated beads by flow  
 138 cytometry.



139

140

141 **Figure 3S**

142 **There are no apparent differences in the anatomy of the cerebral vasculature**

143 **amongst WT, MASP-2<sup>-/-</sup>, MASP-1/3<sup>-/-</sup>, C4<sup>-/-</sup> and fB<sup>-/-</sup> mice.** The anastomotic line

144 between the middle cerebral artery and the anterior cerebral artery has been drawn

145 and shown in green in each brain of the assessed groups (A). The distance of the

146 anastomotic line to the midline at 4mm and 6mm from the frontal pole of the brain

147 (dfm, B) is calculated and reported in the graph (WT and C4<sup>-/-</sup>, n=3; MASP-2<sup>-/-</sup> and

148 fB, n=4; MASP-1/3<sup>-/-</sup>, n=5)(C). Data are reported as column plots and SD (bars), one

149 way ANOVA, Kruskal-Wallis test, Dunn's multiple comparisons test.

150

151 **SUPPLEMENTAL REFERENCES**

- 152 1. De Simoni MG, Rossi E, Storini C, Pizzimenti S, Echart C, Bergamaschini L: **The**  
153 **powerful neuroprotective action of C1-inhibitor on brain ischemia-reperfusion**  
154 **injury does not require C1q.** *Am J Pathol* 2004, **164**:1857–1863.
- 155 2. Storini C, Rossi E, Marrella V, Distaso M, Veerhuis R, Vergani C, Bergamaschini  
156 L, De Simoni M-G: **C1-inhibitor protects against brain ischemia-reperfusion**  
157 **injury via inhibition of cell recruitment and inflammation.** *Neurobiol Dis* 2005,  
158 **19**:10–17.
- 159 3. Orsini F, Villa P, Parrella S, Zangari R, Zanier ER, Gesuete R, Stravalaci M,  
160 Fumagalli S, Ottria R, Reina JJ, Paladini A, Micotti E, Ribeiro-Viana R, Rojo J,  
161 Pavlov VI, Stahl GL, Bernardi A, Gobbi M, De Simoni M-G: **Targeting Mannose**  
162 **Binding Lectin Confers Long Lasting Protection with a Surprisingly Wide**  
163 **Therapeutic Window in Cerebral Ischemia.** *Circulation* 2012, **126**:1484–94.
- 164 4. Yanamoto H, Nagata I, Niitsu Y, Xue JH, Zhang Z, Kikuchi H: **Evaluation of**  
165 **MCAO stroke models in normotensive rats: standardized neocortical infarction**  
166 **by the 3VO technique.** *Exp Neurol* 2003, **182**:261–274.
- 167 5. Perego C, Fumagalli S, De Simoni M-G: **Temporal pattern of expression and**  
168 **colocalization of microglia/macrophage phenotype markers following brain**  
169 **ischemic injury in mice.** *J Neuroinflammation* 2011, **8**:174.
- 170 6. Zanier ER, Fumagalli S, Perego C, Pischutta F, De Simoni M-G: **Shape**  
171 **descriptors of the “never resting” microglia in three different acute brain injury**  
172 **models in mice.** *Intensive Care Med Exp* 2015, **3**:39.

173 7. Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T,  
174 Preibisch S, Rueden C, Saalfeld S, Schmid B, Tinevez J-Y, White DJ, Hartenstein V,  
175 Eliceiri K, Tomancak P, Cardona A: **Fiji: an open-source platform for biological-**  
176 **image analysis.** *Nat Methods* 2012, **9**:676–682.

177 8. Hasan MR, Herz J, Hermann DM, Doeppner TR: **Intravascular perfusion of**  
178 **carbon black ink allows reliable visualization of cerebral vessels.** *J Vis Exp* 2013.

179